GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Black Bird Biotech BBBT · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$36,323

FY2014FY2023

Net income

−$836,135

FY2014FY2023

Free cash flow

−$233,056

FY2014FY2023

Shareholders' equity

—

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$36,323$82,563$104,458$57,604$5,163—————
Gross profit$13,307−$55,906$19,587$29,359——————
Operating income−$314,655−$1.3m−$1.5m−$80,306−$80,306−$83,538−$76,231−$75,739−$85,916−$76,810
Net income−$836,135−$1.7m−$1.8m−$163,628−$121,967−$121,110−$110,014−$106,268−$112,470−$99,519
Diluted earnings per share-0.00-0.01-0.01-0.00-0.00-0.00-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets—$218,508$774,204$126,150$973$4,733$1,573$14,513$12,455$22,628
Cash and short-term investments—$44,448$499,766$52,974—$4,733$1,573$14,513$12,455$22,628
Total liabilities—$868,678$103,994$98,541$1.1m$1.0m$899,291$802,217$693,891$591,594
Debt—$669,775$58,333$45,617—$792,008$712,750$650,000$570,000$500,000
Shareholders' equity—−$650,170$670,210$27,609−$1.1m−$1.0m−$897,718−$787,704−$681,436−$568,966
Shares outstanding1,457m311m301m165m86m86m86m86m86m86m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$233,056−$1.0m−$992,428−$619,465−$131,143−$76,098−$75,690−$77,942−$80,173−$81,556
Capital spending—−$4−$5,702−$5−$5,702−$5,702————
Free cash flow−$233,056−$1.0m−$998,130−$619,470−$136,845−$81,800−$75,690−$77,942−$80,173−$81,556

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Revenue$3,937$12,922$7,385$12,079$25,739$30,943$13,802$22,552
Gross profit$1,418$6,991$3,386$1,512$13,380$12,288$5,832$920
Operating income−$10,884−$94,496−$82,673−$126,501−$178,258−$480,554−$503,020−$654,193
Net income−$131,227−$196,955−$451,195−$241,022−$271,328−$522,594−$670,359−$885,578
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$98,779$106,349$191,165$218,508$168,514$181,252$289,488$774,204
Cash and short-term investments$5,729$6,720$7,234$44,448$66,176$52,522$105,560—
Debt$745,232$887,014$709,453$669,775$655,083$481,986$228,750—
Shareholders' equity−$922,778−$871,289−$726,004−$650,170−$657,660−$395,045−$148$670,210

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-14.2%——
Operating income57.7%30.4%16.0%
Net income72.2%47.2%25.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-35.8%2.3%——
Operating margin-1348.3%-1115.7%——
Net margin-2098.6%-1591.0%——

Valuation history

At each fiscal year end

FY2023
Price to sales0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%8433%46445%-88%-33%3389%15170%32070%338%9369%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-1 split · 29 Jun 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.